🇺🇸 FDA
Patent

US 11401317

Human-CD123-targeting chimeric receptor ligand and application thereof

granted A61KA61K40/11A61K40/31

Quick answer

US patent 11401317 (Human-CD123-targeting chimeric receptor ligand and application thereof) held by Nanjing Legend Biotech Co., Ltd expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Nanjing Legend Biotech Co., Ltd
Grant date
Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K40/11, A61K40/31, A61K40/4217, A61P